title: Sunitinib 2 weeks on, 1 off: strengths and weaknesses.
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan PhD Program, Sapienza University of Rome, Rome, Italy roberto.iacovelli@ieo.it.
authors.forename: R
authors.initials: R
authors.lastname: Iacovelli
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan.
authors.forename: E
authors.initials: E
authors.lastname: Verri
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan.
authors.forename: M
authors.initials: M
authors.lastname: Cossu Rocca
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan.
authors.forename: G
authors.initials: G
authors.lastname: Aurilio
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan.
authors.forename: D
authors.initials: D
authors.lastname: Cullurà
authors.affiliation: Medical Oncology Unit of Urogenital and Head & Neck Tumors, European Institute of Oncology, Milan.
authors.forename: F
authors.initials: F
authors.lastname: Nolé
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles